HOME > TOP STORIES
TOP STORIES
-
BUSINESS “Appropriate Expressions” of Disease Awareness Ads Being Tested
January 7, 2013
-
ORGANIZATION Member Companies to Begin Enforcing New COP in FY2013: JPMA President Teshirogi
January 7, 2013
-
ORGANIZATION NHO to Review Calculation Method for Clinical Trial Costs
December 28, 2012
-
REGULATORY 2nd Abe Cabinet Inaugurated; Industry Awaits Decision on Perpetuation of Premium for New Drug Development
December 27, 2012
-
REGULATORY LDP to Finalize Tax Reform Outline for FY2013 by Late January
December 26, 2012
-
ORGANIZATION JMA to Discuss JPMA’s Transparency Guidelines with JPMA, Related Medical Organizations
December 25, 2012
-
REGULATORY MHLW to Establish a Venue for Discussions to Review Policies for OTC Switching of Lifestyle Disease Treatments
December 21, 2012
-
REGULATORY Osaka’s Healthcare Plan Highlights Differences in Definition of “Frequent Deliveries”
December 21, 2012
-
REGULATORY CSIMC Recommends New Rules on Reducing Prices of Long-Listed Drugs
December 21, 2012
-
REGULATORY MHLW to Revise and Consider Legislation of Ethical Guidelines for Clinical Research
December 20, 2012
-
REGULATORY Pharmaceutical Industry Welcomes Incoming Abe Administration
December 19, 2012
-
BUSINESS Takeda Faces Generic Entry for Candesartan in US
December 18, 2012
-
BUSINESS Pfizer Specialty Care Chief Hopeful about Japan Vaccine Market, Novel RA Treatment
December 17, 2012
-
BUSINESS Elmed Eisai, Kobayashi Kako Get Their Allegra Generics Listed
December 14, 2012
-
BUSINESS Zydus to Build New Plant in India for Japan-Bound Generics
December 13, 2012
-
REGULATORY Strategy Council Proposes Revamped Framework to Oversee Entire Life Innovation Budgets
December 12, 2012
-
BUSINESS Mochida Revving Up Collaboration Efforts in Biosimilars
December 11, 2012
-
REGULATORY Long-Listed Products Not Granted Premium Should Be Exempted from New Rule: FPMAJ’s Kamoya
December 10, 2012
-
BUSINESS Actavis Eyes 3 Monoclonal Antibodies for Entry into Japanese Biosimilar Market: EVP
December 10, 2012
-
BUSINESS With Spiriva Combination Product in PIII, BI Not Fear Competition in COPD Market: Chairman Barner
December 7, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…